Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
J Am Acad Dermatol ; 84(2): 340-347, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32711093

ABSTRACT

BACKGROUND: Merkel cell carcinoma (MCC) management typically includes surgery with or without adjuvant radiation therapy (aRT). Major challenges include determining surgical margin size and whether aRT is indicated. OBJECTIVE: To assess the association of aRT, surgical margin size, and MCC local recurrence. METHODS: Analysis of 188 MCC cases presenting without clinical nodal involvement. RESULTS: aRT-treated patients tended to have higher-risk tumors (larger diameter, positive microscopic margins, immunosuppression) yet had fewer local recurrences (LRs) than patients treated with surgery only (1% vs 15%; P = .001). For patients who underwent surgery alone, 7 of 35 (20%) treated with narrow margins (defined as ≤1.0 cm) developed LR, whereas 0 of 13 patients treated with surgical margins greater than 1.0 cm developed LR (P = .049). For aRT-treated patients, local control was excellent regardless of surgical margin size; only 1% experienced recurrence in each group (1 of 70 with narrow margins ≤1 cm and 1 of 70 with margins >1 cm; P = .56). LIMITATIONS: This was a retrospective study. CONCLUSIONS: Among patients treated with aRT, local control was superb even if significant risk factors were present and margins were narrow. We propose an algorithm for managing primary MCC that integrates risk factors and optimizes local control while minimizing morbidity.


Subject(s)
Carcinoma, Merkel Cell/therapy , Critical Pathways/standards , Dermatologic Surgical Procedures/methods , Neoplasm Recurrence, Local/epidemiology , Skin Neoplasms/therapy , Aged , Aged, 80 and over , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/mortality , Carcinoma, Merkel Cell/pathology , Dermatologic Surgical Procedures/standards , Dermatologic Surgical Procedures/statistics & numerical data , Disease-Free Survival , Female , Follow-Up Studies , Humans , Male , Margins of Excision , Middle Aged , Neoplasm Recurrence, Local/diagnosis , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/prevention & control , Neoplasm Staging , Practice Guidelines as Topic , Radiotherapy, Adjuvant/standards , Radiotherapy, Adjuvant/statistics & numerical data , Retrospective Studies , Risk Assessment/methods , Risk Factors , Skin Neoplasms/diagnosis , Skin Neoplasms/mortality , Skin Neoplasms/pathology , Time-to-Treatment/standards , Time-to-Treatment/statistics & numerical data
2.
Curr Treat Options Oncol ; 17(7): 34, 2016 07.
Article in English | MEDLINE | ID: mdl-27262708

ABSTRACT

OPINION STATEMENT: Non-melanoma skin cancer (NMSC) is the most common malignancy in the USA, with cutaneous squamous cell carcinomas (cSCCs) constituting approximately 20 % of all NMSC. While cSCCs typically behave in an indolent fashion and can be cured with local destructive or surgical methods, a small subset metastasizes and induces significant morbidity and mortality. Identifying and aggressively treating these "high-risk" cSCCs (HRcSCCs) is thus paramount. Recent improvements in staging cSCCs appear to offer better risk stratification than earlier staging criteria. Radiologic imaging and sentinel lymph node biopsy may be beneficial in certain cases of HRcSCC, although more studies are needed before these techniques should be uniformly incorporated into management. Surgery with complete margin control, such as that offered by the Mohs micrographic technique, represents the first-line treatment for these tumors. Radiation therapy is likely most beneficial in the adjuvant setting. Chemotherapy is typically best reserved for patients with metastatic or locally advance disease that is not controllable with surgical and/or radiation therapies. Newer targeted treatments, such as EGFR inhibitors and immunotherapies may offer greater efficacy in these settings, although further evaluation is needed.


Subject(s)
Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/therapy , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Animals , Biopsy , Carcinoma, Squamous Cell/etiology , Carcinoma, Squamous Cell/prevention & control , Combined Modality Therapy , Diagnostic Imaging , Disease Management , Follow-Up Studies , Humans , Neoplasm Grading , Neoplasm Staging , Skin Neoplasms/etiology , Skin Neoplasms/prevention & control , Treatment Outcome
4.
Adv Radiat Oncol ; 1(4): 244-251, 2016.
Article in English | MEDLINE | ID: mdl-28740894

ABSTRACT

PURPOSE: Merkel cell carcinoma (MCC) is a rare and often aggressive skin cancer. Typically, surgery is the primary treatment. Postoperative radiation therapy (PORT) is often recommended to improve local control. It is unclear whether PORT is indicated in patients with favorable Stage IA head and neck (HN) MCC. METHODS AND MATERIALS: We conducted a retrospective analysis of 46 low-risk HN MCC cases treated between 2006 and 2015. Inclusion criteria were defined as a primary tumor size of ≤ 2 cm, negative pathological margins, negative sentinel lymph node biopsy, and no immunosuppression. Local recurrence (LR) was defined as tumor recurrence within 2 cm of the primary surgical bed and estimated with the Kaplan-Meier method. RESULTS: Omission of PORT was offered to all 46 patients, of which 23 patients received PORT and 23 did not. No patient received adjuvant chemotherapy. There were no significant differences in surgical margins, tumor size, depth, lympho-vascular invasion status, or demographics between the two patient groups. Median follow-up for all patients was 3.7 years. Six of the 23 patients who did not receive PORT developed an LR. Compared to the group that received PORT, there was a significantly higher risk of LR in the group treated without PORT (26% vs. 0%, P = .02). Median time to LR was 11 months. All local failures were effectively salvaged. There was no difference in MCC-specific and overall survival between the 2 groups. CONCLUSIONS: For patients with HN MCC, omission of PORT was associated with a significantly higher risk of local recurrence even among those patients with the lowest-risk tumors (i.e., Stage IA without immune suppression). Thus, it is important to weigh the benefits of PORT against the side effect profile on a case-specific basis for each patient.

5.
J Am Acad Dermatol ; 71(4): 599.e1-599.e12; quiz 610, 599.e12, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25219716

ABSTRACT

While most cancers have shown both decreased incidence and mortality over the past several decades, the incidence of melanoma has continued to grow, and mortality has only recently stabilized in the United States and in many other countries. Certain populations, such as men >60 years of age and lower socioeconomic status groups, face a greater burden from disease. For any given stage and across all ages, men have shown worse melanoma survival than women, and low socioeconomic status groups have increased levels of mortality. Novel risk factors can help identify populations at greatest risk for melanoma and can aid in targeted early detection. Risk assessment tools have been created to identify high-risk patients based on various factors, and these tools can reduce the number of patients needed to screen for melanoma detection. Diagnostic techniques, such as dermatoscopy and total body photography, and new technologies, such as multispectral imaging, may increase the accuracy and reliability of early melanoma detection.


Subject(s)
Early Detection of Cancer/standards , Melanoma/diagnosis , Melanoma/epidemiology , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiology , Adult , Aged , Biopsy, Needle , Dermoscopy/standards , Dermoscopy/trends , Early Detection of Cancer/trends , Education, Medical, Continuing , Female , Forecasting , Humans , Incidence , Male , Mass Screening/standards , Mass Screening/trends , Microscopy, Confocal , Middle Aged , Patient Education as Topic , Practice Guidelines as Topic , Risk Assessment , Spectrum Analysis , United States/epidemiology
6.
J Am Acad Dermatol ; 71(4): 611.e1-611.e10; quiz 621-2, 2014 Oct.
Article in English | MEDLINE | ID: mdl-25219717

ABSTRACT

New evidence has accumulated over the past several years that supports improved melanoma outcomes associated with both clinician and patient screening. Population-based and workplace studies conducted in Australia and the Unites States, respectively, have shown decreases in the incidence of thick melanoma and overall melanoma mortality, and a year-long statewide screening program in Germany has shown a nearly 50% reduction in mortality 5 years after the screening ended. Current melanoma screening guidelines in the United States are inconsistent among various organizations, and therefore rates of both physician and patient skin examinations are low. As policymaking organizations update national screening recommendations in the United States, the latest research reviewed in part II of this continuing medical education article should be considered to establish the most effective recommendations. Patient and provider education will be necessary to ensure that appropriate patients receive recommended screening.


Subject(s)
Early Detection of Cancer/standards , Melanoma/diagnosis , Melanoma/epidemiology , Skin Neoplasms/diagnosis , Skin Neoplasms/epidemiology , Adult , Aged , Biopsy, Needle , Dermoscopy/standards , Dermoscopy/trends , Early Detection of Cancer/trends , Education, Medical, Continuing , Female , Forecasting , Health Promotion/organization & administration , Humans , Male , Mass Screening/standards , Mass Screening/trends , Microscopy, Confocal/standards , Microscopy, Confocal/trends , Middle Aged , Patient Education as Topic , Practice Guidelines as Topic , SEER Program , Spectrum Analysis/standards , Spectrum Analysis/trends , United States/epidemiology
7.
J Clin Oncol ; 32(8): 745-51, 2014 Mar 10.
Article in English | MEDLINE | ID: mdl-24493717

ABSTRACT

PURPOSE: Itraconazole, a US Food and Drug Administration-approved antifungal drug, inhibits the Hedgehog (HH) signaling pathway, a crucial driver of basal cell carcinoma (BCC) tumorigenesis, and reduces BCC growth in mice. We assessed the effect of itraconazole on the HH pathway and on tumor size in human BCC tumors. PATIENTS AND METHODS: Patients with ≥ one BCC tumor > 4 mm in diameter were enrolled onto two cohorts to receive oral itraconazole 200 mg twice per day for 1 month (cohort A) or 100 mg twice per day for an average of 2.3 months (cohort B). The primary end point was change in biomarkers: Ki67 tumor proliferation and HH activity (GLI1 mRNA). Secondary end points included change in tumor size in a subset of patients with multiple tumors. RESULTS: A total of 29 patients were enrolled, of whom 19 were treated with itraconazole. Itraconazole treatment was associated with two adverse events (grade 2 fatigue and grade 4 congestive heart failure). Itraconazole reduced cell proliferation by 45% (P = .04), HH pathway activity by 65% (P = .03), and reduced tumor area by 24% (95% CI, 18.2% to 30.0%). Of eight patients with multiple nonbiopsied tumors, four achieved partial response, and four had stable disease. Tumors from untreated control patients and from those previously treated with vismodegib showed no significant changes in proliferation or tumor size. CONCLUSION: Itraconazole has anti-BCC activity in humans. These results provide the basis for larger trials of longer duration to measure the clinical efficacy of itraconazole, especially relative to other HH pathway inhibitors.


Subject(s)
Antineoplastic Agents/administration & dosage , Carcinoma, Basal Cell/drug therapy , Itraconazole/administration & dosage , Skin Neoplasms/drug therapy , Administration, Oral , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , California , Carcinoma, Basal Cell/chemistry , Carcinoma, Basal Cell/genetics , Carcinoma, Basal Cell/pathology , Cell Proliferation/drug effects , Chile , Disease Progression , Drug Administration Schedule , Female , Humans , Itraconazole/adverse effects , Ki-67 Antigen/analysis , Male , Middle Aged , RNA, Messenger/analysis , Remission Induction , Skin Neoplasms/chemistry , Skin Neoplasms/genetics , Skin Neoplasms/pathology , Time Factors , Transcription Factors/genetics , Treatment Outcome , Tumor Burden/drug effects , Zinc Finger Protein GLI1
8.
Pediatr Dermatol ; 31(1): 21-6, 2014.
Article in English | MEDLINE | ID: mdl-24283549

ABSTRACT

The relationship between food and environmental allergens in contributing to eczema risk is unclear on a multiethnic population level. Our purpose was to determine whether sensitization to specific dietary and environmental allergens as measured according to higher specific immunoglobulin E (IgE) levels is associated with eczema risk in children. National Health and Nutrition Examination Survey participants ages 1 to 17 years were asked whether they had ever received a diagnosis of eczema from a physician (n = 538). Total and specific serum IgE levels for four dietary allergens (egg, cow's milk, peanut, and shrimp) and five environmental allergens (dust mite, cat, dog, Aspergillus, and Alternaria) were measured. Logistic regression was used to examine the association between eczema and IgE levels. In the United States, 10.4 million children (15.6%) have a history of eczema. Eczema was more common in black children (p < 0.001) and in children from families with higher income and education (p = 0.01). The median total IgE levels were higher in children with a history of eczema than in those without (66.4 vs 50.6 kU/L, p = 0.004). In multivariate analysis adjusted for age, race, sex, family income, household education, and physician-diagnosed asthma, eczema was significantly associated with sensitization to cat dander (odds ratio [OR] = 1.2, 95% confidence interval [CI] 1.05, 1.4, p = 0.009) and dog dander (OR = 1.5, 95% CI, 1.2, 1.7, p < 0.001). After correction for multiple comparisons, only sensitization to dog dander remained significant. U.S. children with eczema are most likely to be sensitized to dog dander. Future prospective studies should further explore this relationship.


Subject(s)
Allergens/immunology , Eczema/epidemiology , Eczema/immunology , Food Hypersensitivity/ethnology , Food Hypersensitivity/immunology , Nutrition Surveys/statistics & numerical data , Adolescent , Child , Child, Preschool , Cross-Sectional Studies , Ethnicity/statistics & numerical data , Female , Humans , Immunoglobulin E/blood , Infant , Male , Multivariate Analysis , Prevalence , Risk Factors , United States/epidemiology
9.
J Am Acad Dermatol ; 67(5): 803.e1-12, quiz 815-6, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23062903

ABSTRACT

Skin cancer is the most common cancer in the United States. Exposure to ultraviolet radiation is a known risk factor for skin cancer but is also the principal means by which the body obtains vitamin D. Several studies have suggested that vitamin D plays a protective role in a variety of internal malignancies. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar protective effect. These noncalcemic actions of vitamin D have called into question whether the current recommended intake of vitamin D is too low for optimal health and cancer prevention. Part I will review the role of vitamin D in the epidermis; part II will review the role of vitamin D in keratinocyte-derived tumors to help frame the discussion on the possible role of vitamin D in the prevention of skin cancer.


Subject(s)
Epidermis/physiology , Skin Neoplasms/physiopathology , Vitamin D/physiology , Animals , Calcifediol/physiology , Epidermis/physiopathology , Food , Humans , Keratinocytes/physiology , Receptors, Calcitriol/physiology , Skin Neoplasms/prevention & control , Skin Pigmentation/physiology , Sunlight , Sunscreening Agents , Vitamin D/blood
10.
J Am Acad Dermatol ; 67(5): 817.e1-11; quiz 827-8, 2012 Nov.
Article in English | MEDLINE | ID: mdl-23062904

ABSTRACT

The role of vitamin D in health maintenance and disease prevention in fields ranging from bone metabolism to cancer is currently under intensive investigation. A number of epidemiologic studies have suggested that vitamin D may have a protective effect on cancer risk and cancer-associated mortality. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar risk reducing effect. Potential mechanisms of action include inhibition of the hedgehog signaling pathway and upregulation of nucleotide excision repair enzymes. The key factor complicating the association between vitamin D and skin cancer is ultraviolet B radiation. The same spectrum of ultraviolet B radiation that catalyzes the production of vitamin D in the skin also causes DNA damage that can lead to epidermal malignancies. Part II of this continuing medical education article will summarize the literature on vitamin D and skin cancer to identify evidence-based optimal serum levels of vitamin D and to recommend ways of achieving those levels while minimizing the risk of skin cancer.


Subject(s)
Skin Neoplasms/physiopathology , Vitamin D/physiology , Carcinoma, Basal Cell/physiopathology , Carcinoma, Basal Cell/prevention & control , Carcinoma, Squamous Cell/physiopathology , Carcinoma, Squamous Cell/prevention & control , DNA Damage/physiology , Hedgehog Proteins/physiology , Humans , Keratinocytes/physiology , Receptors, Calcitriol/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology , Skin Neoplasms/blood , Skin Neoplasms/prevention & control , Vitamin D/blood
12.
J Clin Oncol ; 29(22): 3078-84, 2011 Aug 01.
Article in English | MEDLINE | ID: mdl-21709199

ABSTRACT

PURPOSE: In light of inverse relationships reported in observational studies of vitamin D intake and serum 25-hydroxyvitamin D levels with risk of nonmelanoma skin cancer (NMSC) and melanoma, we evaluated the effects of vitamin D combined with calcium supplementation on skin cancer in a randomized placebo-controlled trial. METHODS: Postmenopausal women age 50 to 79 years (N = 36,282) enrolled onto the Women's Health Initiative (WHI) calcium/vitamin D clinical trial were randomly assigned to receive 1,000 mg of elemental calcium plus 400 IU of vitamin D3 (CaD) daily or placebo for a mean follow-up period of 7.0 years. NMSC and melanoma skin cancers were ascertained by annual self-report; melanoma skin cancers underwent physician adjudication. RESULTS: Neither incident NMSC nor melanoma rates differed between treatment (hazard ratio [HR], 1.02; 95% CI, 0.95 to 1.07) and placebo groups (HR, 0.86; 95% CI, 0.64 to 1.16). In subgroup analyses, women with history of NMSC assigned to CaD had a reduced risk of melanoma versus those receiving placebo (HR, 0.43; 95% CI, 0.21 to 0.90; P(interaction) = .038), which was not observed in women without history of NMSC. CONCLUSION: Vitamin D supplementation at a relatively low dose plus calcium did not reduce the overall incidence of NMSC or melanoma. However, in women with history of NMSC, CaD supplementation reduced melanoma risk, suggesting a potential role for calcium and vitamin D supplements in this high-risk group. Results from this post hoc subgroup analysis should be interpreted with caution but warrant additional investigation.


Subject(s)
Calcium, Dietary/administration & dosage , Cholecalciferol/administration & dosage , Dietary Supplements , Melanoma/epidemiology , Melanoma/prevention & control , Skin Neoplasms/epidemiology , Skin Neoplasms/prevention & control , Aged , Confounding Factors, Epidemiologic , Female , Follow-Up Studies , Humans , Incidence , Kaplan-Meier Estimate , Middle Aged , Odds Ratio , Postmenopause , Research Design , Risk Assessment , Risk Factors , Treatment Outcome , United States/epidemiology , Vitamin D/analogs & derivatives , Vitamin D/blood , Women's Health
13.
Cancer Causes Control ; 22(7): 1067-71, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21637987

ABSTRACT

BACKGROUND: Sun protection messages in the United States emphasize sunscreen use, although its efficacy in skin cancer prevention remains controversial. METHODS: We used data from NHANES 2003-2006, restricted to adult whites (n = 3,052) to evaluate how Americans protect themselves from the sun. Participants completed questionnaires on the frequency with which they used sunscreen, wore a hat, long sleeves, or stayed in the shade, in addition to the number of sunburns in the past year. RESULTS: Although using sunscreen is the most common sun protective behavior (30%), frequent sunscreen use was not associated with fewer sunburns. However, the odds of multiple sunburns were significantly lower in individuals who frequently avoided the sun by seeking shade (OR = 0.70, p < 0.001) or wearing long sleeves (OR = 0.73, p = 0.01). CONCLUSIONS: Our findings suggest that shade and protective clothing may be more effective than sunscreen, as typically used by Americans.


Subject(s)
Information Dissemination , Protective Clothing/statistics & numerical data , Sunburn/prevention & control , Sunlight/adverse effects , Sunscreening Agents/therapeutic use , Adult , Carcinoma/epidemiology , Carcinoma/prevention & control , Female , Health Knowledge, Attitudes, Practice , Humans , Information Dissemination/methods , Male , Middle Aged , Nutrition Surveys , Program Evaluation , Skin Neoplasms/epidemiology , Skin Neoplasms/prevention & control , Sunburn/epidemiology , United States/epidemiology , White People/statistics & numerical data , Young Adult
15.
J Invest Dermatol ; 131(5): 1025-8, 2011 May.
Article in English | MEDLINE | ID: mdl-21160496

ABSTRACT

Pachyonychia congenita (PC) is a rare, autosomal dominant keratin disorder caused by mutations in four genes (KRT6A, KRT6B, KRT16, or KRT17). The International PC Research Registry is a database with information on patients' symptoms as well as genotypes. We sought to describe the heterogeneity of clinical symptoms and to investigate possible genotype-phenotype correlations in patients with two types of K16 mutations, p.Asn125 and p.Arg127, causing the PC-16 subtype of PC. We found that clinical symptoms depended on the type of amino-acid substitution. Patients with p.Asn125Asp and p.Arg127Pro mutations exhibited more severe disease than patients carrying p.Asn125Ser and p.Arg127Cys mutations in terms of age of onset of symptoms, extent of nail involvement, and impact on daily quality of life. We speculate that amino-acid substitutions causing larger, more disruptive changes to the K16 protein structure, such as a change in amino-acid charge in the p.Asn125Asp mutation or a bulky proline substitution in the p.Arg127Pro mutation, may also lead to more severe disease phenotypes. The variation in phenotypes seen with different substitutions at the same mutation site suggests a genotype-phenotype correlation. Knowledge of the exact gene defect is likely to assist in predicting disease prognosis and clinical management.


Subject(s)
Genetic Association Studies , Keratin-16/genetics , Mutation/genetics , Pachyonychia Congenita/genetics , Pachyonychia Congenita/pathology , Child , Child, Preschool , Female , Humans , Keratoderma, Palmoplantar/genetics , Male , Quality of Life , Severity of Illness Index
16.
Cancer Causes Control ; 21(12): 2315-6, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20882333

ABSTRACT

To investigate the relationship between UV-induced skin photodamage and 25(OH) vitamin D levels, we performed a cross-sectional study in 45 female subjects aged >40. Menopausal status, smoking status, skin cancer history, oral supplement use, and season of blood draw were recorded and serum 25(OH)D measured. A single-blinded, dermatologist evaluated standardized digital facial images for overall photodamage, erythema/telangiectasias, hyperpigmentation, number of lentigines, and wrinkling. Adjusting for age and season of blood collection, women with lower photodamage scores were associated with a 5-fold increased odds of being vitamin D insufficient (OR 5.0, 95% CI: 1.1, 23). Low scores for specific photodamage parameters including erythema/telangiectasias, hyperpigmentation, and wrinkling were also significantly associated with vitamin D insufficiency. Our results suggest an association between skin aging and 25(OH)D levels.


Subject(s)
Skin Aging/physiology , Vitamin D Deficiency/epidemiology , Vitamin D/blood , White People/statistics & numerical data , Adult , Aged , Cross-Sectional Studies , Face , Female , Humans , Middle Aged , Odds Ratio , Skin Diseases/epidemiology , Skin Diseases/etiology , Skin Pigmentation/physiology , Sunlight/adverse effects , Vitamin D Deficiency/blood
17.
Fertil Steril ; 91(5): 1686-91, 2009 May.
Article in English | MEDLINE | ID: mdl-18672236

ABSTRACT

OBJECTIVE: To evaluate the expression of biomarkers of implantation, glycodelin A (GdA), osteopontin (OPN), lysophosphatidic acid receptor 3 (LPA3), and HOXA10, in eutopic endometrium of women with and without endometriosis. DESIGN: Prospective observational study. SETTING: Clinical research center. PATIENT(S): Twenty-four women with endometriosis and 23 healthy volunteers of similar age. INTERVENTION(S): Secretory phase endometrial biopsy. MAIN OUTCOME MEASURE(S): Expression of immunohistochemical staining intensity and localization of GdA, OPN, LPA3, and HOXA10 in eutopic endometrium. RESULT(S): Endometrial GdA expression was significantly reduced in patients after cycle day 22. The endometrium from women with endometriosis also showed decreased expression of OPN in the late secretory phase and LPA3 and HOXA10 expression in the midsecretory and late secretory phases. CONCLUSION(S): The decreased expression of these four biomarkers of implantation may indicate impaired endometrial receptivity in patients with endometriosis, providing one explanation for the subfertility observed even in women with few pelvic implants. Because many of these markers are P dependent, these findings suggest the possibility of reduced endometrial P action in this population.


Subject(s)
Embryo Implantation , Glycoproteins/analysis , Homeodomain Proteins/analysis , Osteopontin/analysis , Pregnancy Proteins/analysis , Receptors, Lysophosphatidic Acid/analysis , Adult , Biomarkers , Endometriosis , Endometrium/chemistry , Female , Glycodelin , Homeobox A10 Proteins , Homeodomain Proteins/genetics , Humans , Immunohistochemistry , Osteopontin/genetics , Prospective Studies
18.
Am J Clin Pathol ; 131(1): 49-57, 2009 Jan.
Article in English | MEDLINE | ID: mdl-19095565

ABSTRACT

Evaluation of the bone marrow is a critical component of accurate staging and surveillance for recurrent disease in neuroblastoma. The value of routine immunohistochemical analysis of otherwise histologically negative bone marrow biopsy specimens has not been adequately evaluated. By using synaptophysin, chromogranin, and beta-catenin, immunohistochemical analysis performed on otherwise histologically negative bone marrow specimens identified isolated tumor cells (ITCs) in 9.1%, 5.0%, and 10.0% of 220 biopsy specimens, respectively. Overall survival, as estimated by the Kaplan-Meier method, was not significantly different between patients with and without ITCs (P = .357). Of the immunohistochemical markers evaluated, beta-catenin showed the greatest sensitivity for identifying ITCs in the bone marrow and showed reactivity in primary tumor samples. We found that the presence of ITCs identified by immunohistochemical analysis may predict the persistence of disease but does not show significant overall survival differences. We also identified beta-catenin as a sensitive immunohistochemical marker of primary and metastatic neuroblastoma.


Subject(s)
Bone Marrow/pathology , Neuroblastoma/pathology , beta Catenin/analysis , Biopsy , Bone Marrow Examination , Child , Child, Preschool , Chromogranins/analysis , False Positive Reactions , Female , Humans , Immunohistochemistry , Infant , Infant, Newborn , Kaplan-Meier Estimate , Male , Neoplasm Metastasis/pathology , Synaptophysin/analysis
19.
Pediatr Blood Cancer ; 45(1): 43-7, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15880471

ABSTRACT

BACKGROUND: Pre-operative red blood cell (RBC) transfusions are often recommended for patients with sickle cell disease (SCD) who require elective surgery under general anesthesia. However, definitive randomized studies demonstrating the benefit of transfusions in this setting have not been conducted. In particular, the merits of transfusion prior to minor or low-risk surgical procedures in children with SCD have not been demonstrated. PROCEDURE: We hypothesized that children with sickle cell anemia (Hb SS) who have minor elective surgical procedures develop few complications even without pre-operative transfusion. We accessed our Comprehensive Sickle Cell Program's Database to identify all such procedures performed during a 13-year period. Medical records were reviewed to characterize the surgical procedure, the use of transfusions, and perioperative complications. RESULTS: Twenty-eight children with Hb SS had a total of 38 minor surgical procedures. No perioperative transfusions were given in 34 of the cases (85%). Five of these 34 surgeries (15%) were associated with minor post-operative complications (fever or transient pain). No post-operative acute chest syndrome was encountered. CONCLUSIONS: Minor or low-risk elective surgical procedures in children with Hb SS may not routinely require pre-operative transfusion. A randomized clinical trial to compare transfusion with no transfusion for minor surgical procedures is needed.


Subject(s)
Anemia, Sickle Cell , Anesthesia, General , Elective Surgical Procedures/methods , Minor Surgical Procedures/methods , Safety , Adolescent , Blood Transfusion , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Postoperative Complications/epidemiology , Preoperative Care , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...